Pretreatment levels of plasma renin activity predict ambulatory blood pressure response to valsartan in essential hypertension

Journal of Human Hypertension

Volumn 23, Issue 10, 2009, Pages 683-686

  Minami, J ^a   Furukata, S ^a   Ishimitsu, T ^a   Matsuoka, H ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; RENIN; VALSARTAN;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BLOOD SAMPLING; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE INCREASE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERTENSION; JAPANESE; MALE; PLASMA RENIN ACTIVITY; PRACTICE GUIDELINE; PREDICTION; RADIOIMMUNOASSAY; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TREATMENT RESPONSE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; HUMANS; HYPERTENSION; JAPAN; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOIMMUNOASSAY; RENIN; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 70349466587     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2009.31     Document Type: Article

References (11)

1. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF et al. Guidelines for management of hypertension: Report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18: 139-185.
2. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 Guidelines for the Management of Arterial Hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.
3. Ogrihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32 3-107.
4. Minami J, Ishimitsu T, Matsuoka H. Pretreatment plasma renin activity levels correlate with the blood pressure response to telmisartan in essential hypertension. Am J Hypertens 2008; 21: 10-13.
5. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003; 42: 1137-1143.
6. O'Brien E, Barton J, Nussberger J, Mulcahy D, Jensen C, Dicker P et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007; 49: 276-284.
7. Oparil S, Dyke S, Harris F, Kief J, James D, Hester A et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996; 18: 797-810.
8. Sealey JE, Blumenfeld J, Laragh JH. Prorenin cryo-activation as a possible cause of normal renin levels in patients with primary aldosteronism. J Hypertens 2005; 23: 459-460.
9. Alderman MH, Cohen HW, Sealey JE, Laragh JH. Plasma renin activity levels in hypertensive persons: Their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens 2004; 17: 1-7.
10. Sealey JE, Laragh JH. Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises. Am J Hypertens 2009; 22: 112-121.
11. Sealey JE. Plasma renin activity and plasma prorenin assays. Clin Chem 1991; 37: 1811-1819.